Ralf Gutzmer Selected Research

Autoimmune Diseases (Autoimmune Disease)

11/2019	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172).
1/2017	Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
12/2007	Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha.
7/2006	Critical involvement of IL-12 in IFN-gamma induction by calcineurin antagonists in activated human lymphocytes.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ralf Gutzmer Research Topics

Disease

137	Melanoma (Melanoma, Malignant) 05/2024 - 04/2007
66	Neoplasms (Cancer) 03/2024 - 07/2004
30	Neoplasm Metastasis (Metastasis) 05/2024 - 04/2008
24	Skin Neoplasms (Skin Cancer) 12/2023 - 06/2014
13	Basal Cell Carcinoma (Rodent Ulcer) 10/2023 - 06/2014
12	Atopic Dermatitis (Atopic Eczema) 09/2022 - 03/2002
11	Squamous Cell Carcinoma (Epidermoid Carcinoma) 12/2023 - 10/2012
11	Inflammation (Inflammations) 09/2022 - 03/2002
11	Psoriasis (Pustulosis Palmaris et Plantaris) 09/2021 - 12/2003
10	Skin Diseases (Skin Disease) 01/2020 - 06/2005
8	Brain Neoplasms (Brain Tumor) 09/2023 - 01/2018
6	Exanthema (Rash) 01/2023 - 01/2010
6	Disease Progression 01/2023 - 08/2007
6	Neutropenia 01/2021 - 07/2012
5	Uveal melanoma 10/2023 - 07/2017
5	Fever (Fevers) 01/2023 - 07/2012
4	Arthralgia (Joint Pain) 01/2020 - 07/2012
4	Autoimmune Diseases (Autoimmune Disease) 11/2019 - 07/2006
4	Necrosis 01/2011 - 12/2003
3	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 10/2023 - 01/2021
3	Merkel Cell Carcinoma 01/2023 - 10/2020
3	Fatigue 10/2021 - 07/2012
3	Nausea 10/2021 - 07/2012
3	Infections 01/2021 - 07/2006
3	Lymphatic Metastasis 11/2020 - 01/2016
3	Colitis 11/2019 - 01/2017
3	Myositis (Idiopathic Inflammatory Myopathies) 01/2019 - 05/2018
3	Hypertension (High Blood Pressure) 10/2018 - 01/2017
2	COVID-19 01/2022 - 01/2021
2	Alopecia (Baldness) 10/2021 - 10/2008
2	Carcinogenesis 10/2021 - 06/2010
2	Lymphoma (Lymphomas) 10/2021 - 03/2007
2	Pancreatitis 01/2021 - 01/2018
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 10/2020
2	Sarcoma (Soft Tissue Sarcoma) 01/2019 - 03/2002
2	Myalgia 10/2018 - 01/2018
2	Drug-Related Side Effects and Adverse Reactions 06/2017 - 04/2016
2	Vomiting 07/2013 - 07/2012

Drug/Important Bio-Agent (IBA)

43	Immune Checkpoint InhibitorsIBA 05/2024 - 04/2015
26	IpilimumabIBA 10/2023 - 01/2013
24	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 05/2024 - 05/2015
22	pembrolizumabIBA 02/2024 - 01/2016
22	NivolumabIBA 10/2023 - 04/2015
18	Histamine (Histamine Dihydrochloride)FDA Link 09/2022 - 03/2002
17	VemurafenibIBA 04/2024 - 10/2012
11	binimetinibIBA 04/2024 - 01/2017
11	encorafenibIBA 04/2024 - 01/2018
10	AntibodiesIBA 05/2023 - 01/2016
8	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 05/2023 - 07/2017
7	InterferonsIBA 10/2023 - 06/2005
6	Biomarkers (Surrogate Marker)IBA 10/2023 - 11/2016
6	HhAntag691IBA 04/2022 - 05/2014
6	sonidegibIBA 11/2021 - 06/2015
6	Dacarbazine (DIC)FDA LinkGeneric 01/2020 - 10/2009
6	Histamine H4 ReceptorsIBA 01/2020 - 01/2009
5	dabrafenibIBA 09/2023 - 07/2012
5	Creatine Kinase (Creatine Phosphokinase)IBA 01/2023 - 01/2017
5	Proteins (Proteins, Gene)FDA Link 01/2020 - 10/2006
5	Monoclonal AntibodiesIBA 01/2020 - 09/2014
5	CytokinesIBA 02/2012 - 12/2003
4	cemiplimabIBA 10/2023 - 01/2020
4	cyclopropapyrroloindoleIBA 01/2023 - 10/2020
4	talimogene laherparepvecIBA 01/2023 - 12/2018
4	ChemokinesIBA 10/2021 - 01/2015
4	Histamine Receptors (Histamine Receptor)IBA 01/2020 - 01/2011
4	Programmed Cell Death 1 ReceptorIBA 01/2020 - 01/2017
4	Interferon alpha-2 (Roferon-A)FDA Link 05/2018 - 01/2013
3	DNA (Deoxyribonucleic Acid)IBA 02/2024 - 03/2002
3	Adrenal Cortex Hormones (Corticosteroids)IBA 09/2023 - 10/2020
3	cobimetinibIBA 01/2023 - 01/2020
3	B7-H1 AntigenIBA 01/2023 - 11/2018
3	mogamulizumabIBA 01/2023 - 01/2021
3	Sirolimus (Rapamycin)FDA Link 10/2021 - 06/2014
3	Lipase (Acid Lipase)FDA Link 01/2021 - 04/2015
3	AntigensIBA 01/2021 - 01/2011
3	Alanine Transaminase (SGPT)IBA 01/2020 - 04/2015
3	Mitogen-Activated Protein KinasesIBA 05/2019 - 01/2019
3	ParaffinIBA 11/2015 - 06/2010
3	Formaldehyde (Formol)FDA Link 11/2015 - 06/2010
3	InterleukinsIBA 02/2012 - 06/2005
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2005 - 12/2003
2	Denosumab FDA Link 03/2024 - 07/2019
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2024 - 01/2021
2	Interferon-alpha (Interferon Alfa)IBA 10/2023 - 12/2007
2	atezolizumabIBA 01/2023 - 01/2020
2	Rituximab (Mabthera)FDA Link 01/2022 - 01/2021
2	MTOR InhibitorsIBA 10/2021 - 06/2014
2	Imiquimod (Aldara)FDA LinkGeneric 12/2020 - 01/2002
2	AutoantibodiesIBA 01/2020 - 12/2007
2	Messenger RNA (mRNA)IBA 12/2013 - 03/2009
2	1- ((5- chloro- 1H- indol- 2- yl)carbonyl)- 4- methylpiperazineIBA 12/2013 - 01/2009
2	Sorafenib (BAY 43-9006)FDA Link 09/2013 - 01/2010

Therapy/Procedure

103	Therapeutics 05/2024 - 07/2006
18	Immunotherapy 04/2024 - 02/2012
11	Radiotherapy 10/2022 - 05/2014
9	Drug Therapy (Chemotherapy) 01/2022 - 03/2007
5	Lymph Node Excision (Lymph Node Dissection) 01/2022 - 08/2013
4	Aftercare (After-Treatment) 05/2023 - 01/2017
2	Drug Tapering 01/2021 - 01/2010
2	Organ Transplantation 01/2019 - 11/2017